Role of minimal residual disease monitoring in acute promyelocytic leukemia treated with arsenic trioxide in frontline therapy.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Blood

• Publication date

  2011-11-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood-2011-11-393264PMID 22374701
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adjuvant Therapy Reduces Rate of Dissemination but Shortens Survival Thereafter.

  2015cited by this paper
• Emerging new approaches for the treatment of acute promyelocytic leukemia

  2011cited by this paper
• Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia.

  2011cited by this paper
• Should minimal residual disease monitoring be the standard of care for all patients with acute promyelocytic leukemia?

  2011cited by this paper
• Modern approaches to treating acute promyelocytic leukemia.

  2011cited by this paper
• Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.

  2010cited by this paper
• Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data.

  2010cited by this paper
• Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

  2009cited by this paper
• Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.

  2009cited by this paper
• Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.

  2009cited by this paper
• Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.

  2009cited by this paper
• Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia

  2009cited by this paper
• Review Articles (434 articles)

  2008cited by this paper
• Acute promyelocytic leukemia: from highly fatal to highly curable.

  2008cited by this paper
• A rapid, one step assay for simultaneous detection of FLT3/ITD and NPM1 mutations in AML with normal cytogenetics

  2008cited by this paper
• Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention

  2007cited by this paper
• Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia.

  2007cited by this paper
• Guidelines on the management of acute myeloid leukaemia in adults

  2006cited by this paper
• Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity.

  2006cited by this paper
• Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program

  2003cited by this paper
• Comprehensive validation of a real-time quantitative bcr-abl assay for clinical laboratory use.

  2003cited by this paper
• Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program

  2003cited by this paper
• Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors.

  2002cited by this paper
• Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.

  2001cited by this paper
• Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease

  1999cited by this paper
• Therapy of molecular relapse in acute promyelocytic leukemia.

  1999cited by this paper
• Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial.

  1998cited by this paper
• Early Detection of Relapse by Prospective Reverse Transcriptase-Polymerase Chain Reaction Analysis of the PML/RARα Fusion Gene in Patients With Acute Promyelocytic Leukemia Enrolled in the GIMEMA-AIEOP Multicenter “AIDA” Trial

  1998cited by this paper

• Venetoclax induces mitochondrial apoptosis and autophagy to overcome arsenic trioxide resistance in acute promyelocytic leukemia

  2026cites this paper
• Acute Promyelocytic Leukemia with double minute chromosomes: a rare case with high relapse risk

  2025cites this paper
• Prognostic significance of MRD and its correlation with arsenic concentration in pediatric acute promyelocytic leukemia: a retrospective study by SCCLG-APL group

  2025cites this paper
• Curative strategies for high-risk acute promyelocytic leukemia.

  2025cites this paper
• Acute Promyelocytic Leukemia in the Real World: Understanding Outcome Differences and How We Can Improve Them

  2024cites this paper
• Measurable Residual Disease Analysis by Flow Cytometry and Correlation With Molecular Measurable Residual Disease in Acute Promyelocytic Leukemia: A Real-World Prospective Study.

  2024cites this paper
• Cytoreductive chemotherapy in induction therapy plays a key role in the prognosis of patients with low‐risk acute promyelocytic leukaemia

  2024cites this paper
• Clinical validation of the Ion Torrent Oncomine Myeloid Assay GX v2 on the Genexus Integrated Sequencer as a stand-alone assay for single-nucleotide variants, insertions/deletions, and fusion genes: Challenges, performance, and perspectives.

  2024cites this paper
• Analytical validation of an automated semiconductor-based next-generation sequencing assay for detection of DNA and RNA alterations in myeloid neoplasms.

  2023cites this paper
• Revealing the Mysteries of Acute Myeloid Leukemia: From Quantitative PCR through Next-Generation Sequencing and Systemic Metabolomic Profiling

  2022cites this paper
• PML‐RARA transcript levels at the end of induction therapy are associated with prognosis in non‐high‐risk acute promyelocytic leukaemia with all‐trans retinoic acid plus arsenic in front‐line therapy: long‐term follow‐up of a single‐centre cohort study

  2021cites this paper
• The complete story of less than complete responses: The evolution and application of acute myeloid leukemia clinical responses.

  2021cites this paper
• Molecular Testing for Post-transplant Disease Surveillance

  2021cites this paper
• Evaluation of arsenic species in leukocytes and granulocytes of acute promyelocytic leukemia patients treated with arsenic trioxide.

  2021cites this paper
• A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide

  2020cites this paper
• Clinical significance of increased PML-RARa transcripts after induction therapy for acute promyelocytic leukaemia

  2020cites this paper
• A Quality Initiative of the Program in Evidence-Based Care (PEBC), Ontario Health (Cancer Care Ontario) Minimal Residual Disease Testing in Acute Leukemia

  2020cites this paper
• Measurable residual disease after the first consolidation predicts the outcomes of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy

  2020cites this paper
• Management of relapse in acute promyelocytic leukaemia treated with up‐front arsenic trioxide‐based regimens

  2020cites this paper
• Acute Promyelocytic Leukemia: A Constellation of Molecular Events around a Single PML-RARA Fusion Gene

  2020cites this paper
• Using minimal (measurable) residual disease assessments to guide decision-making for timing of allogeneic transplantation in acute myeloid leukemia.

  2019cites this paper
• Clinical Validation of a Myeloid Next-Generations Sequencing Panel for Single Nucleotide Variants, Indels, and Fusion Genes.

  2019cites this paper
• Molecular remission as a therapeutic objective in acute promyelocytic leukemia

  2018cites this paper
• Role of minimal residual disease in the management of acute myeloid leukemia—a case-based discussion

  2018cites this paper
• Catalase down-regulation in cancer cells exposed to arsenic trioxide is involved in their increased sensitivity to a pro-oxidant treatment

  2018cites this paper
• Minimal Residual Disease in APL

  2018cites this paper
• NPM1 for MRD? Droplet Like It's Hot!

  2017cites this paper
• Precision medicine in acute myeloid leukemia: Hope, hype or both?

  2016cites this paper
• Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia

  2016cites this paper
• Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemia

  2016cites this paper
• Current first- and second-line treatment options in acute promyelocytic leukemia.

  2016cites this paper
• PML–RARα kinetics and impact of FLT3–ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy

  2016cites this paper
• A novel approach to quantitating leukemia fusion transcripts by qRT-PCR without the need for standard curves.

  2015cites this paper
• The Epidemiological Scale of Alzheimer’s Disease

  2015cites this paper
• Leucémie aiguë promyélocytaire : à propos d’un cas clinique

  2015cites this paper
• HOX/PBX interaction as a therapeutic target in acute myeloid leukaemia

  2015cites this paper
• Immunotherapy of Leukemic Stem Cells using Natural Killer Cell Lines

  2015cites this paper
• Acute myeloid leukaemia: challenges and real world data from India

  2015cites this paper
• Molecular Monitoring as a Path to Cure Acute Promyelocytic Leukemia

  2015cites this paper
• Incorporation of arsenic trioxide in induction therapy improves survival of patients with newly diagnosed acute promyelocytic leukaemia

  2014influential citation
• Outcomes and prognostic factors of first relapsed acute promyelocytic leukemia patients undergoing salvage therapy with intravenous arsenic trioxide and chemotherapy

  2014cites this paper
• Guidelines on the diagnosis and treatment for acute promyelocytic leukemia: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Guidelines Project: Associação Médica Brasileira - 2013

  2014cites this paper
• New Strategies in Acute Promyelocytic Leukemia: Moving to an Entirely Oral, Chemotherapy-Free Upfront Management Approach

  2014cites this paper
• Targeted Next-Generation Sequencing at Copy-Number Breakpoints for Personalized Analysis of Rearranged Ends in Solid Tumors

  2014cites this paper
• Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells

  2014influential citation
• Long‐term efficacy of low‐dose all‐trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post‐remission therapy in newly diagnosed acute promyelocytic leukaemia

  2014cites this paper
• Inching toward cure of acute myeloid leukemia: a summary of the progress made in the last 50 years

  2014cites this paper
• Haplotype counting by next-generation sequencing for ultrasensitive human DNA detection.

  2014cites this paper
• [Not Available].

  2014cites this paper
• Molecular monitoring of minimal residual disease in acute leukemia

  2014cites this paper
• Qualification biologique des greffons de tissu ovarien autoconservé : Contribution à la recherche de maladie résiduelle en cas de pathologie néoplasique

  2014cites this paper
• Minimal Residual Disease in Acute Myeloid Leukemia

  2014cites this paper
• The leukemias: a half-century of discovery.

  2014cites this paper
• Minimal residual disease testing in acute leukemia

  2013cites this paper
• Postconsolidation maintenance and monitoring in patients with acute promyelocytic leukemia.

  2013cites this paper
• Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical results and open questions

  2013cites this paper
• Minimal residual disease in acute myeloid leukaemia

  2013cites this paper
• MicroRNAs Contribute to Promyelocyte Apoptosis in As2O3-Treated APL Cells

  2013cites this paper
• Minimal residual disease in acute myeloid leukemia: coming of age.

  2012cites this paper